EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

EvolveImmune Therapeutics has achieved a preclinical milestone in its collaboration with AbbVie, nominating a development candidate against a solid tumor target. This achievement triggers an $18 million milestone payment to EvolveImmune and validates its proprietary EVOLVE T cell engager platform. The collaboration aims to develop multispecific biologics for oncology, leveraging an approach designed to amplify and sustain the tumor-killing capacity of T-cells.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments